LivaNova (NASDAQ:LIVN) Raised to Strong-Buy at Barclays

LivaNova (NASDAQ:LIVN) was upgraded by investment analysts at Barclays to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.

A number of other equities analysts have also recently commented on the stock. Needham & Company LLC lifted their price objective on shares of LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, August 18th. KeyCorp upped their target price on shares of LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, June 22nd. Freedom Capital upgraded LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Finally, Mizuho boosted their price objective on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, LivaNova has a consensus rating of “Moderate Buy” and an average price target of $87.75.

LivaNova Stock Down 0.0%

Shares of LIVN opened at $75.91 on Wednesday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. The stock has a market capitalization of $4.18 billion, a price-to-earnings ratio of 22.46 and a beta of 0.87. LivaNova has a 1 year low of $48.82 and a 1 year high of $85.76. The business’s 50 day simple moving average is $78.86 and its 200-day simple moving average is $75.00.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The firm had revenue of $390.59 million during the quarter, compared to analyst estimates of $380.50 million. During the same period last year, the firm posted $1.05 earnings per share. LivaNova’s revenue for the quarter was up 10.8% compared to the same quarter last year. As a group, equities analysts expect that LivaNova will post 3.78 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Brooke Story sold 2,300 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the completion of the sale, the director owned 7,488 shares in the company, valued at approximately $609,672.96. This trade represents a 23.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $78.01, for a total transaction of $273,035.00. Following the transaction, the director directly owned 4,434 shares of the company’s stock, valued at approximately $345,896.34. This represents a 44.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 7,450 shares of company stock valued at $591,839 in the last 90 days. Company insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

Several institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in shares of LivaNova by 12.5% during the third quarter. GAMMA Investing LLC now owns 2,068 shares of the company’s stock valued at $158,000 after buying an additional 230 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in shares of LivaNova by 59.7% in the third quarter. Farther Finance Advisors LLC now owns 452 shares of the company’s stock worth $35,000 after buying an additional 169 shares during the period. Avidian Wealth Enterprises LLC bought a new stake in shares of LivaNova during the 3rd quarter worth approximately $752,000. Cim Investment Management Inc. bought a new stake in shares of LivaNova during the 2nd quarter worth approximately $248,000. Finally, Tidal Investments LLC purchased a new position in LivaNova during the 2nd quarter valued at $204,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and markets technologies for the treatment of cardiovascular and neurological conditions. The company’s principal businesses are organized around its Cardiopulmonary and Neuromodulation segments.

Its cardiopulmonary portfolio includes heart-lung machines, oxygenators, perfusion systems and other equipment used during cardiopulmonary bypass procedures, as well as technologies designed to support cardiac surgery and related clinical applications.